Aldosterone Enzyme Immunoassay Kit

Name: Aldosterone Enzyme Immunoassay Kit
SKU: DEIABL242
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum, EDTA, Heparin Plasma, Urine, Fecal Extracts, Tissue Culture Media

Intended Use

The Aldosterone Immunoassay kit is designed to quantitatively measure Aldosterone present in extracted serum and plasma, or in urine, extracted dried fecal samples, and tissue culture media samples. This kit measures total aldosterone in extracted serum or plasma and fecal samples.

Contents of Kit

1. Coated Clear 96 Well Plate
2. Aldosterone Standard
3. Aldosterone Antibody
4. Aldosterone Conjugate
5. Assay Buffer Concentrate
6. Wash Buffer Concentrate
7. TMB Substrate
8. Stop Solution
9. Plate Sealer

Storage

4°C

Performance Characteristics

##OVERNIGHT INCUBATION##

##Sensitivity and Limit of Detection##
Sensitivity was calculated by comparing the OD's for twenty wells run for each of the B0 and standard #6. The detection limit was determined at two (2) standard deviations from the B0 alon

General Description

Aldosterone, C21H28O5, is a mineralocorticoid first isolated by the husband and wife team of Simpson and Tait at University College, London in 1953. Initially called electrocortin, 21 mg was isolated from 500 kg of beef adrenal glands. Aldosterone controls the sodium-potassium balance through the unidirectional salt reabsorption in a variety of tissues and glands. Synthesized from cholesterol in the zona glomerulosa of the adrenal cortex, secretion is regulated through the renin-angiotensin system. Angiotensin II and potassium stimulate primary secretion by increasing the rate of production of the steroid. Peripheral aldosterone levels are dependant on age and body position and in a normal upright adult aldosterone levels are typically less than 300 pg/mL. Aldosterone is typically secreted as the 18-glucuronide and the terahydro-3-glucuronide and this excretion is generally 2-20 μg/24 hour urine collection. Aldosterone measurement is useful in the investigation of primary aldosteronism (i.e., adrenal adenoma or carcinoma and adrenal cortical hyperplasia) and secondary aldosteronism (renovascular disease, salt depletion, potassium loading, cardiac failure with ascites, pregnancy, Bartter syndrome). The renin-angiotensin system is the primary regulator of the synthesis and secretion of aldosterone. Increased concentrations of potassium in the plasma may directly stimulate adrenal production of the hormone. Under physiologic conditions, pituitary adrenocorticotropic hormone is not a major factor in regulating aldosterone secretion.

Standard Curve

Typical Standard Curve - Overnight Incubation

Typical Standard Curve - 2 Hour Incubation

Reconstitution And Storage

All components of this kit should be stored at 4°C until the expiration date of the kit.

Citations

Have you cited DEIABL242 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19

MEDICAL SCIENCE MONITOR

Authors: Wang, Zhongchao; Zhang, Dewei; Wang, Shengming; Jin, Yanhua; Huan, Jianbo; Wu, Yue; Xia, Cheng; Li, Zhe; Qi, Xingshun; Zhang, Duanzhen; Han, Xiumin; Zhu, Xianyang; Qu, Ying; Wang, Qiguang

Abstract

Background: Use of renin-angiotensin-aldosterone system inhibitors in coronavirus disease 2019 (COVID-19) patients lacks evidence and is still controversial. This study was designed to investigate effects of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on clinical outcomes of COVID-19 patients and to assess the safety of ACEIs/ARBs medication. Material/Methods: COVID-19 patients with hypertension from 2 hospitals in Wuhan, China, from 17 Feb to 18 Mar 2020 were retrospectively screened and grouped according to in-hospital medication. We performed 1: 1 propensity score matching (PSM) analysis to adjust for confounding factors. Results: We included 210 patients and allocated them to ACEIs/ARBs (n=81; 46.91% males) or non-ACEIs/ARBs (n=129; 48.06% males) groups. The median age was 68 [interquartile range (IQR) 615-76] and 66 (IQR 59-72.5) years, respectively. General comparison showed mortality in the ACEIs/ARBs group was higher (8.64% vs. 3.88%) but the difference was not significant (P=0.148). ACEIs/ARBs was associated with significantly more cases 7-categorical ordinal scale >2 at discharge, more cases requiring Intensive Care Unit (ICU) stay, and increased values and ratio of days that blood pressure (BP) was above normal range (P<0.05). PSM analysis showed no significant difference in mortality, cumulative survival rate, or other clinical outcomes such as length of in-hospital/ICU stay, BP fluctuations, or ratio of adverse events between groups after adjustment for confounding parameters on admission. Conclusions: We found no association between ACEIs/ARBs and clinical outcomes or adverse events, thus indicating no evidence for discontinuing use of ACEIs/ARBs in the COVID-19 pandemic.

Development and Validation of Criteria for Sparing Confirmatory Tests in Diagnosing Primary Aldosteronism

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Authors: Wang, Kanran; Hu, Jinbo; Yang, Jun; Song, Ying; Fuller, Peter J.; Hashimura, Hikaru; He, Wenwen; Feng, Zhengping; Cheng, Qingfeng; Du, Zhipeng; Wang, Zhihong; Ma, Linqiang; Yang, Shumin; Li, Qifu

Abstract

Context: The Endocrine Society Guidelines for the diagnosis of primary aldosteronism (PA) suggest that confirmatory tests (CFT) are not required when the following criteria are met: plasma aldosterone concentration (PAC) is >20 ng/dL, plasma renin is below detection levels, and hypokalemia is present. The evidence for the applicability of the guideline criteria is limited. Objective: To develop and validate optimized criteria for sparing CFT in the diagnosis of PA. Design and Setting: The optimized criteria were developed in a Chinese cohort using the captopril challenge test, verified by saline infusion test (SIT) and fludrocortisone suppression test (FST), and validated in an Australian cohort. Participants: Hypertensive patients who completed PA screening and CFT. Main Outcome Measure: Diagnostic value of the optimized criteria. Results: In the development cohort (518 PA and 266 non-PA), hypokalemia, PAC, and plasma renin concentration (PRC) were selected as diagnostic indicators by multivariate logistic analyses. The combination of PAC >20 ng/dL plus PRC <2.5 mu IU/mL plus hypokalemia had much higher sensitivity than the guideline criteria (0.36 vs 0.11). The optimized criteria remained superior when the SIT or FST were used as CFT. Non-PA patients were not misdiagnosed by either criteria, but the percentage of patients in whom CFT could be spared was higher with the optimized criteria. In the validation cohort (125 PA and 81 non-PA), the sensitivity of the optimized criteria was also significantly higher (0.12 vs 0.02). Conclusions: Hypertensive patients with PAC >20 ng/dL, PRC <2.5 mu IU/mL, plus hypokalemia can be confidently diagnosed with PA without confirmatory tests.